Heart Tumor Treatment in China for International Patients
A “heart tumor” can mean a benign primary cardiac tumor such as a myxoma, a rare primary malignant cardiac tumor, or cancer that has spread to the heart from another organ. Those are different diseases with different surgery, oncology treatment and prognosis.
Short answer: when a primary benign heart tumor is removable, surgery is usually the main treatment
and outcomes can be excellent. Malignant primary cardiac tumors are much more difficult and often require a
multidisciplinary cardiac-surgery + oncology plan. China has high-volume cardiovascular centers with published
cardiac-tumor experience, but the useful first step for an international patient is a surgeon’s review of the
echocardiogram, cardiac CT/MRI and oncology records — not booking a generic “heart tumor package.”
✓ Benign vs malignant separated
✓ Cardiac surgery + oncology route
✓ Named China centers
✓ No survival or surgery guarantee
Heart Tumors: At a Glance
Myxoma is the most common primary cardiac tumor in adults and most often arises in the left atrium.
Symptomatic benign tumors such as myxoma are generally treated by surgical excision because obstruction or embolization can be dangerous even when pathology is benign.
Primary cardiac sarcomas and other malignant tumors have a much poorer prognosis than benign tumors and often recur despite surgery.
Chinese centers including Fuwai, Beijing Anzhen, Qingdao University Affiliated Hospital and Nanjing Drum Tower have published cardiac-tumor surgical experience.
Clinical and hospital evidence last checked: September 2026.
Primary vs Secondary Heart Tumors
Before discussing treatment, the first question is whether the mass started in the heart or represents tumor spread from somewhere else. “Heart cancer” is not a single diagnosis.
| Category | Examples | Typical treatment question | Why this matters for China hospital selection |
|---|---|---|---|
| Benign primary cardiac tumor | Myxoma, papillary fibroelastoma, lipoma, fibroma and others | Can it be completely and safely removed? Does a valve or other cardiac structure need repair? | Cardiac-surgery experience and imaging are central; oncology may be less important if pathology is clearly benign. |
| Primary malignant cardiac tumor | Angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma and other rare malignancies | Is complete resection technically possible, and what systemic or radiation treatment is appropriate? | The case needs both complex cardiac surgery and rare-tumor oncology; a cardiac-only clinic is not enough. |
| Secondary / metastatic involvement | Cancer from another organ involving the heart or pericardium | Is the cardiac lesion causing obstruction, effusion, arrhythmia or another problem that changes systemic cancer treatment? | The primary cancer usually determines the oncology pathway; surgery is not automatically the main treatment. |
Cardiac Myxoma: The Most Important Benign Heart-Tumor Entity
Cardiac myxoma is benign by histology but can still be dangerous. It can obstruct blood flow,
interfere with valves, trigger arrhythmia or cause embolization if tumor material or clot travels into the circulation.
Once a clinically significant myxoma is diagnosed, timely surgical evaluation is usually appropriate.
A 2024 meta-analysis covering 112 studies and 8,150 patients found that myxoma most commonly involved the left atrium and that outcomes after tumor excision were generally excellent. A current 2026 review from Beijing Anzhen Hospital likewise describes surgical management as a central part of treatment while emphasizing multimodality imaging and long-term follow-up, especially in familial disease.
Left atrium
Myxomas are most often atrial and frequently arise near the interatrial septum. Location determines how the mass affects blood flow and which surgical approach may be used.
Obstruction + embolization risk
Symptoms may worsen abruptly if a mobile tumor obstructs a valve opening or embolizes. The timeline should therefore be decided by a cardiac surgeon rather than by medical-tourism scheduling alone.
Pathology + follow-up
The resected mass should be examined pathologically. Follow-up echocardiography is important, particularly for recurrent or familial myxoma syndromes.
Heart Tumor Symptoms
Symptoms depend more on the tumor’s location, mobility and hemodynamic effect than on size alone. Some cardiac tumors are discovered incidentally.
Shortness of breath
A mass can interfere with filling or outflow and mimic valve disease or heart failure.
Palpitations / arrhythmia
Tumor location can affect cardiac conduction or irritate myocardium and contribute to rhythm disturbance.
Stroke or peripheral embolism
Mobile tumors, particularly friable lesions, can be associated with embolic events.
Fatigue, fever or nonspecific symptoms
Primary cardiac tumors can present with systemic symptoms, and malignant tumors may also present through metastatic or pericardial disease.
Urgent symptoms need urgent local care. New stroke symptoms, fainting, severe chest pain, severe
breathlessness, hemodynamic instability or rapidly worsening heart-failure symptoms should not wait for an
international treatment trip.
How a Heart Tumor Is Diagnosed Before Surgery
| Test | What it can answer | Why a China surgeon may request it |
|---|---|---|
| Echocardiography | Location, mobility, attachment, valve obstruction, chamber effects and hemodynamics. | Often the first key imaging study and essential for understanding how the mass affects cardiac function. |
| Cardiac CT | Anatomic detail, calcification, relationship to coronary vessels and surrounding structures; can help stage thoracic disease. | Useful for surgical planning and for evaluating extension beyond the heart. |
| Cardiac MRI | Tissue characterization, infiltration, chamber/valve relationships and functional information. | Can help distinguish thrombus from tumor and characterize a mass when echocardiography alone is not enough. |
| Whole-body cancer staging | Looks for a primary tumor elsewhere or metastatic disease when malignancy is suspected. | Critical before calling a lesion a “primary heart cancer” and before deciding whether aggressive cardiac surgery makes sense. |
| Pathology | Defines the actual tumor type after resection or biopsy. | Treatment and prognosis depend on histology; imaging cannot replace pathology in malignant-tumor planning. |
Chinese surgical series also describe echocardiography, CT and MRI as important tools in the early diagnosis and surgical planning of primary cardiac tumors.
Can a Heart Tumor Be Removed?
Operability cannot be decided from the diagnosis name alone. Surgeons need to know where the tumor
attaches, whether it invades myocardium, valves, coronary arteries, great vessels or pericardium, whether the mass
can be removed with acceptable cardiac function, and whether cancer has spread elsewhere.
Localized benign tumor
- Clear attachment site
- No major invasive growth
- Complete excision technically possible
- Valve or septum can be repaired/reconstructed if needed
- No reason to suspect widespread malignant disease
Invasive malignant tumor
- Myocardial or great-vessel invasion
- Coronary involvement
- Multiple cardiac sites
- Distant metastases
- Resection would leave unacceptable cardiac function
Heart Tumor Surgery in China
For removable primary benign tumors, surgical resection is the standard treatment. The exact operation depends on where the mass is attached and whether adjacent cardiac structures must be repaired.
Remove the mass and attachment
The surgeon aims to remove the lesion while minimizing embolization and preserving normal cardiac structures.
Septum / valve repair may be needed
If the tumor involves the atrial septum or a valve, resection can require patch reconstruction, valve repair or occasionally valve replacement.
Open or selected minimally invasive surgery
Some benign tumors can be approached through smaller incisions or thoracoscopic techniques, but safety and complete removal matter more than incision size.
Do not choose a hospital only because it advertises “minimally invasive” surgery. A mobile atrial
myxoma, valve tumor, ventricular mass and infiltrative sarcoma can require very different operations. The surgeon
should first review the imaging and define the safest resection plan.
Primary Malignant Heart Tumors: Surgery Is Only Part of the Plan
Primary malignant cardiac tumors are rare and behave very differently from myxoma. Histology can include sarcoma subtypes such as angiosarcoma, myxofibrosarcoma and undifferentiated pleomorphic sarcoma.
Prognosis is substantially worse than for benign tumors. Multiple surgical series show high
recurrence and disease-related mortality in primary cardiac sarcoma. Treatment therefore needs coordinated
cardiac surgery, pathology and oncology, and the value of surgery depends heavily on whether meaningful resection is possible.
Potential components
- Expert pathology review
- Complete staging
- Cardiac-surgery operability review
- Systemic therapy when appropriate
- Radiation planning in selected cases
- Clinical-trial review for rare sarcoma when relevant
Questions to answer before travelling
- Is the tumor truly primary to the heart?
- What is the pathology subtype?
- Can gross-total resection be achieved?
- Is there distant disease?
- What treatment comes after surgery?
- Who coordinates oncology follow-up after returning home?
Heart Tumor Survival Rate and Prognosis
There is no responsible single “heart tumor survival rate.” A completely resected benign atrial
myxoma and an infiltrative primary cardiac sarcoma should not be placed in the same statistic.
Published evidence is consistent on the broad pattern: outcomes after resection of benign primary cardiac tumors are generally very good, while malignant primary tumors have substantially worse outcomes and frequent recurrence. A 2018 Chinese series of 212 surgically resected primary cardiac tumors reported favorable outcomes for benign tumors but recurrence or disease-related death in all seven patients with primary cardiac sarcoma. A separate Nanjing Drum Tower series reported much better five-year survival for myxoma than for malignant tumors.
Often excellent after complete resection
For isolated myxoma or another removable benign tumor, long-term outcomes can be very favorable, although follow-up remains important.
Histology and resectability dominate prognosis
Primary cardiac sarcomas can recur rapidly. Complete resection, tumor subtype, metastatic disease and response to systemic treatment all matter.
Needs pathology + staging
A meaningful prognosis estimate requires the exact pathology, tumor location, surgical plan and cancer stage — not just the words “heart tumor.”
Hospitals in China to Consider for a Heart Tumor Case
This is a case-fit shortlist, not a numerical ranking. Published cardiac-tumor experience and a practical international-patient pathway are separate factors.
Beijing · Cardiovascular specialty center
Foreign-facing service confirmed
Fuwai Hospital, Chinese Academy of Medical Sciences
Fuwai is the strongest first center on this shortlist for a surgery-focused heart-tumor case. Its official site has a dedicated cardiac-myxoma disease page, lists surgeons whose practice explicitly includes cardiac tumors and myxoma resection, and describes a Special Medical Center that serves foreign patients working in China and other international-facing patients. Fuwai teams have also published large cardiac-myxoma and malignant-cardiac-tumor series.
Beijing · Multidisciplinary international route
International pathway confirmed
Peking Union Medical College Hospital (PUMCH)
PUMCH is particularly useful when the mass diagnosis is uncertain or a malignant case requires coordinated oncology, pathology and multiple specialties. Its official International Medical Services provides an explicit foreign-patient booking and inpatient pathway. We do not present PUMCH as a cardiac-tumor volume leader without case-specific evidence; its strength here is the multidisciplinary and international-access route.
Beijing · Published cardiac tumor expertise
International access: verify
Beijing Anzhen Hospital
Anzhen is relevant because its cardiovascular-surgery teams continue to publish on cardiac tumors. A 2024 paper reviewed surgical treatment of right-sided cardiac tumors, and a 2026 review from its Department of Cardiovascular Surgery covers modern cardiac-myxoma management. For an overseas patient, current foreign-patient intake and self-pay arrangements should be verified before travel.
Which center fits your imaging and pathology?
Send the echo/CT/MRI and any pathology report. We can separate a surgery-first case from one that needs a combined cardiac-oncology route.
How Much Does Heart Tumor Surgery Cost in China?
There is no reliable one-price “heart tumor surgery package.” Cost changes substantially depending
on whether the case is a straightforward atrial myxoma resection or a complex operation requiring valve repair,
vascular reconstruction, repeat surgery, prolonged ICU care or malignant-tumor treatment.
Imaging and staging
Cardiac echo, CT/MRI, coronary evaluation when appropriate, laboratory testing and cancer staging can all affect the estimate.
Complexity drives cost
Surgical approach, cardiopulmonary bypass time, valve or septal reconstruction, blood products and pathology can change the hospital bill.
ICU + ward + oncology
ICU duration, postoperative complications, inpatient days, rehabilitation and any chemotherapy/radiation plan can add substantially to total cost.
For Parkmega, the correct workflow is: medical records → named cardiac surgeon/hospital review → proposed operation → written estimate. We do not publish an invented universal USD range before that process.
What Records Should You Send to a Chinese Cardiac Surgeon?
Core cardiac file
- Latest echocardiogram report and images/video if available
- Cardiac CT images/report
- Cardiac MRI images/report if performed
- ECG and rhythm history
- Coronary angiography/CT coronary study if already performed
- Current cardiac medications
- Prior cardiac surgery history
If malignancy is suspected or confirmed
- Pathology report and slides/blocks if available
- PET/CT or other staging scans
- Biopsy report
- Primary cancer history if the lesion may be metastatic
- Previous chemotherapy / radiation / immunotherapy
- Latest oncology summary
- Any previous operability opinion
Questions to Ask Before Travelling to China
1. What does the hospital think the mass is?
Myxoma, another benign tumor, thrombus, primary malignancy or metastasis? The treatment plan starts here.
2. Is complete removal expected?
Ask whether the goal is complete excision, partial/palliative resection, biopsy or no surgery.
3. What cardiac reconstruction is expected?
Will surgery require septal patching, valve repair/replacement, great-vessel reconstruction or another major procedure?
4. What pathology is needed?
If the diagnosis is malignant or uncertain, ask whether existing slides can be reviewed before travel.
5. What happens after surgery?
Clarify ICU stay, expected hospitalization, follow-up imaging and whether oncology treatment is planned.
6. What is the written estimated cost?
Ask what the estimate includes and which complications, blood products, implants or oncology treatments are excluded.
How Parkmega Handles a Heart Tumor Case
Organize imaging and diagnosis
We identify whether there is echo, cardiac CT/MRI, pathology and oncology staging and what is still missing.
Choose the correct hospital route
A likely myxoma is primarily a cardiac-surgery question; an invasive sarcoma needs cardiac surgery plus oncology.
Request a case review
Where appropriate, records are sent for a named-center review to ask about diagnosis, operability and proposed treatment.
Plan only after a medical response
Travel, visa/invitation, expected stay and cost planning begin after the hospital defines a realistic treatment route.
Send the Echo, CT/MRI and Pathology Before Choosing a Hospital in China
We’ll identify whether the case looks surgery-first, oncology-first or needs a combined cardiac-tumor team, then help route the records to a relevant Chinese center for review before you plan travel.
✓ No obligation to book
✓ Operability reviewed before travel
✓ No guaranteed outcome
Related China Treatment Guides
Frequently Asked Questions
Direct answers to the main heart-tumor questions patients ask before seeking treatment in China.
What is a heart tumor?
A heart or cardiac tumor is an abnormal mass involving the heart. It may be a benign primary tumor such as myxoma, a rare primary malignant cardiac tumor, or cancer that has spread to the heart from another site. Treatment depends on the exact tumor type, location and extent.
What are the symptoms of a heart tumor?
Symptoms vary with tumor location and can include shortness of breath, palpitations or arrhythmia, fainting, heart-failure-like symptoms, embolic events such as stroke, and systemic symptoms such as fatigue or fever. Some tumors are found incidentally on cardiac imaging.
Is a heart tumor always cancer?
No. Most primary cardiac tumors are benign, and cardiac myxoma is the most common primary cardiac tumor in adults. Primary malignant tumors such as cardiac sarcoma are much rarer but substantially more aggressive. Cancer from another organ can also involve the heart secondarily.
Can a tumor on the heart be removed?
Many localized benign cardiac tumors can be surgically removed, often with very good outcomes. Operability is more complex for malignant tumors and depends on invasion into myocardium, valves, coronary arteries or great vessels, metastatic disease and whether adequate heart function can be preserved after resection.
What is the survival rate for a heart tumor?
There is no single meaningful survival rate for all heart tumors. Completely resected benign tumors such as myxoma generally have excellent outcomes. Primary malignant cardiac tumors have a much poorer prognosis and high recurrence risk. A personal estimate requires exact pathology, staging, tumor location and resectability.
Which hospital in China treats heart tumors?
Fuwai Hospital in Beijing is a strong surgery-focused option because its official site and published literature document cardiac-tumor and myxoma expertise, and it has a foreign-facing Special Medical Center. PUMCH is useful for complex multidisciplinary or uncertain malignant cases and has a clear international-patient pathway. Beijing Anzhen Hospital also has current published cardiac-tumor expertise, but overseas intake should be verified for the individual case.
How much does heart tumor surgery cost in China?
There is no fixed national heart-tumor surgery package. The cost depends on the tumor location, surgical approach, cardiopulmonary bypass, valve or vascular reconstruction, ICU and ward stay, pathology, complications and whether oncology treatment is also required. A meaningful estimate should come from a named hospital after imaging review.
What records should I send for a heart tumor review in China?
Send the echocardiogram report and images if available, cardiac CT and/or MRI, ECG, prior cardiac history and current medication. If malignancy is suspected, also send pathology, biopsy material if available, PET/CT or other staging scans, oncology treatment history and any previous surgical-opinion report.
Evidence and Hospital Sources
- Primary and secondary cardiac tumors — clinical review. Review of presentation, diagnosis, surgery and outcomes; emphasizes that most primary cardiac tumors are benign, while malignant tumors have markedly worse prognosis. PubMed.
- Cardiac myxoma meta-analysis, 2024. Analysis of 112 studies and 8,150 patients; confirms cardiac myxoma as the most common primary cardiac tumor and reports generally excellent outcomes after excision. PubMed.
- Chinese 212-patient primary cardiac-tumor surgical series. Affiliated Hospital of Qingdao University; 16-year experience with myxoma, other benign tumors and malignant tumors. PubMed.
- Nanjing Drum Tower Hospital — 115 surgical patients. Chinese 15-year series showing substantially better long-term outcomes for myxoma than malignant cardiac tumors. PubMed.
- Fuwai Hospital — official cardiac myxoma page. Official hospital disease information describes cardiac myxoma, its common left-atrial location and embolic risk. Fuwai Hospital.
- Fuwai Hospital — cardiac tumor surgical expertise. Official surgeon profile explicitly includes surgical treatment of cardiac tumors and cardiac myxoma resection. Fuwai surgeon profile.
- Fuwai Hospital — Special Medical Center. Official hospital material describes a foreign-facing clinical service integrating cardiovascular medicine and surgery. Fuwai Special Medical Center.
- Fuwai Hospital — published myxoma surgical experience. Fuwai publications include large cardiac-myxoma surgical series. PubMed.
- Beijing Anzhen Hospital — Cardiac Myxoma: From Pathogenesis to Management, 2026. Current review from the Department of Cardiovascular Surgery discusses multimodal imaging, surgical management and follow-up. PubMed.
- Beijing Anzhen Hospital — right cardiac system tumors, 2024. Surgical experience with right-sided cardiac tumors from the hospital’s Department of Cardiac Surgery. PubMed.
- Peking Union Medical College Hospital — International Medical Services. Official foreign-patient booking and inpatient pathway. PUMCH International Medical Services.
Hospital-selection note: published surgical experience, current physician availability and international-patient intake are different questions. A center should be contacted for the specific case before flights or treatment deposits are arranged.
Medical note: This page is for medical-travel research and hospital matching. It is not medical advice and does not establish operability, diagnosis or prognosis for an individual patient.
Get a Cardiac-Surgery or Cardiac-Oncology Case Review Before You Travel
Send the echocardiogram, cardiac CT/MRI, pathology and cancer staging that you already have. We’ll organize the file, identify the appropriate China route and help request a case-specific review from a relevant center.